| This article has been cited by |
| 1 | Antacid Therapy in Coronary Artery Disease and Heart Failure: Proton Pump Inhibitors vs. H2 Receptor Blockers | |
| Muzamil Khawaja,Janki Thakker,Riyad Kherallah,Masafumi Kitakaze,Hani Jneid,Dominick J. Angiolillo,Yochai Birnbaum |
| Cardiovascular Drugs and Therapy.2022;() |
| [DOI] |
|
| 2 | The risks of PPI therapy | |
| Paul Moayyedi,Grigorios I. Leontiadis |
| Nature Reviews Gastroenterology & Hepatology.2012;9(3)132 |
| [DOI] |
|
| 3 | ADP-Receptor Inhibitors in the Perioperative Period: The Good, the Bad, and the Ugly | |
| Adriana Dana Oprea,Wanda M. Popescu |
| Journal of Cardiothoracic and Vascular Anesthesia.2013;27(4)779 |
| [DOI] |
|
| 4 | Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters | |
| Kelly Bleasby,Robert Houle,Michael Hafey,Meihong Lin,Jingjing Guo,Bing Lu,Rosa I. Sanchez,Kerry L. Fillgrove |
| Viruses.2021;13(8)1566 |
| [DOI] |
|
| 5 | Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters | |
| A. Vidya,M. Kalaivani,K. R. Venugopal,L M Patnaik |
| Viruses.2014;13(8)35 |
| [DOI] |
|
| 6 | Recent Safety Concerns With Proton Pump Inhibitors | |
| Joan Chen,Yuhong Cathy Yuan,Grigorios I. Leontiadis,Colin W. Howden |
| Journal of Clinical Gastroenterology.2012;46(2)93 |
| [DOI] |
|
| 7 | Inconsistencies surrounding the risk of adverse outcomes with concomitant use of clopidogrel and proton pump inhibitors | |
| Chun Shing Kwok,Yoon Kong Loke |
| Expert Opinion on Drug Safety.2012;11(2)275 |
| [DOI] |
|
| 8 | Efficacy, Safety, and Tolerability of Pantoprazole Magnesium in the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease (GERD): A Prospective, Multicenter, Post-Marketing Observational Study | |
| José María Remes-Troche,Sergio Sobrino-Cossío,Julio César Soto-Pérez,Oscar Teramoto-Matsubara,Miguel Morales-Arámbula,Antonio Orozco-Gamiz,José Luis Tamayo de la Cuesta,Gualberto Mateos |
| Clinical Drug Investigation.2014;34(2)83 |
| [DOI] |
|
